2XX9
Crystal structure of 1-((2-fluoro-4-(3-(trifluoromethyl)-4,5,6,7- tetrahydro-1H-indazol-1-yl)phenyl)methyl)-2-pyrrolidinone in complex with the ligand binding domain of the Rat GluA2 receptor and glutamate at 2.2A resolution.
Summary for 2XX9
| Entry DOI | 10.2210/pdb2xx9/pdb |
| Related | 1FTJ 1FTK 1FTL 1FTM 1FTO 1FW0 1GR2 1LB8 1LB9 1LBB 1LBC 1M5B 1M5C 1M5D 1M5E 1M5F 1MM6 1MM7 1MQD 1MQG 1MQH 1MQI 1MQJ 1MS7 1MXU 1MXV 1MXW 1MXX 1MXY 1MXZ 1MY0 1MY1 1MY2 1MY3 1MY4 1N0T 1NNK 1NNP 1P1N 1P1O 1P1Q 1P1U 1P1W 1SYH 1SYI 1WVJ 1XHY 2AIX 2AL4 2AL5 2ANJ 2CMO 2I3V 2I3W 2UXA 2XX7 2XX8 2XXH 2XXI |
| Descriptor | GLUTAMATE RECEPTOR 2, GLUTAMIC ACID, N,N-DIMETHYL-4-[3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-INDAZOL-1-YL]BENZAMIDE, ... (6 entities in total) |
| Functional Keywords | transport protein, ampa receptor ligand-binding core, ion channel |
| Biological source | RATTUS NORVEGICUS (NORWAY RAT) |
| Cellular location | Cell membrane; Multi-pass membrane protein: P19491 |
| Total number of polymer chains | 3 |
| Total formula weight | 89211.20 |
| Authors | Ward, S.E.,Harries, M.,Aldegheri, L.,Austin, N.E.,Ballantine, S.,Ballini, E.,Bradley, D.M.,Bax, B.D.,Clarke, B.P.,Harris, A.J.,Harrison, S.A.,Melarange, R.A.,Mookherjee, C.,Mosley, J.,DalNegro, G.,Oliosi, B.,Smith, K.J.,Thewlis, K.M.,Woollard, P.M.,Yusaf, S.P. (deposition date: 2010-11-09, release date: 2011-04-06, Last modification date: 2024-10-16) |
| Primary citation | Ward, S.E.,Harries, M.,Aldegheri, L.,Austin, N.E.,Ballantine, S.,Ballini, E.,Bradley, D.M.,Bax, B.D.,Clarke, B.P.,Harris, A.J.,Harrison, S.A.,Melarange, R.A.,Mookherjee, C.,Mosley, J.,Dal Negro, G.,Oliosi, B.,Smith, K.J.,Thewlis, K.M.,Woollard, P.M.,Yusaf, S.P. Integration of Lead Optimization with Crystallography for a Membrane-Bound Ion Channel Target: Discovery of a New Class of Ampa Receptor Positive Allosteric Modulators. J.Med.Chem., 54:78-, 2011 Cited by PubMed Abstract: A novel series of AMPAR positive modulators is described that were identified by high throughput screening. The molecules of the series have been optimized from a high quality starting point hit to afford excellent developability, tolerability, and efficacy profiles, leading to identification of a clinical candidate. Unusually for an ion channel target, this optimization was integrated with regular generation of ligand-bound crystal structures and uncovered a novel chemotype with a unique and highly conserved mode of interaction via a trifluoromethyl group. PubMed: 21128618DOI: 10.1021/JM100679E PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.97 Å) |
Structure validation
Download full validation report
